MENU

FDMT Stock FDMT is expected to report earnings to rise+15.48% to -73 cents per share on August 11

A.I.dvisor
at Tickeron.com
Loading...
FDMT - 4D Molecular Therapeutics
4D Molecular Therapeutics Earnings Graph
Q2'25
Est.
$-0.73
Q1'25
Est.
$-0.86
Q4'24
Missed
by $0.05
Q3'24
Missed
by $0.11
Q2'24
Beat
by $0.05
The last earnings report on March 31 showed earnings per share of -86 cents, meeting the estimate of -86 cents. P/B Ratio (0.555) is normal, around the industry mean (18.696). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). FDMT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. FDMT's P/S Ratio (10000.000) is very high in comparison to the industry average of (286.048). With 552.77K shares outstanding, the current market capitalization sits at 260.81M.

Momentum Indicator for FDMT turns positive, indicating new upward trend

FDMT saw its Momentum Indicator move above the 0 level on July 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on August 01, 2025. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 153 cases where FDMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FDMT moved out of overbought territory on August 04, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where FDMT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FDMT broke above its upper Bollinger Band on August 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.555) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). FDMT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. FDMT's P/S Ratio (10000.000) is very high in comparison to the industry average of (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FDMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. FDMT showed earnings on May 08, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
5858 Horton Street
Phone
+1 510 505-2680
Employees
147
Web
https://www.4dmoleculartherapeutics.com